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Background
Cystic fibrosis (CF) is a major life-limiting genetic disease
leading to severe respiratory symptoms caused by muta-
tions in CF trans membrane conductance regulator
(CFTR), a chloride channel expressed at the apical mem-
brane of epithelial cells. Absence of functional CFTR from
the surface of respiratory cells reduces mucociliary clear-
ance, promoting airways obstruction, chronic infection
and ultimately lung failure [1]. Despite major clinical
advances treating the symptoms, which pushed survival
beyond the second decade (~25 years in Europe), CF is
still a life-limiting condition [2]. However, to further
increase CF patients life expectancy, CF needs to be trea-
ted beyond its symptoms, i.e., through treatments addres-
sing the basic defect associated with CFTR gene mutations
[3]. So far ~1,900 CFTR mutations were reported [4], but
one single mutation, F508del remains the most common
one, as it occurs in ~90% of CF patients in at least one
allele [5] and is associated with a severe clinical phenotype.
Despite that most of efforts are focused on correcting the
F508del-CFTR which causes intracellular retention of the
mutant channel at the endoplasmic reticulum (ER), several
additional strategies are emerging to rescue other (rarer
mutants) which, in some populations, also have high pre-
valence. To this end, CFTR mutations are usually grouped
into functional classes, towards a “mutation-specific”
therapeutic approach by which mutations within the same
functional class can be corrected by the same therapeutic
strategy towards a “personalized medicine” approach [6].
Materials and methods/ results
To apply such strategy CFTR mutations are thus classified
into six main functional categories [7,8], namely: i) class I
mutations (often mutations generating premature stop
codons, e.g., R1162X) prevent protein production; ii) class
II mutations (includes F508del) cause intracellular reten-
tion and premature degradation, thus preventing mutant
CFTR from reaching the cell surface; iii) class III mutants
(e.g., G551D) cause impairment in the channel gating (i.e.,
decreased open probability); iv) class IV mutants have sub-
stantially reduced flow of Cl- ions through the CFTR chan-
nel (e.g., R334W); v) class V mutants include mostly
alternative splicing mutants (e.g., 3272-26A>G) which
allow synthesis of some normal CFTR mRNA (and pro-
tein), albeit at very low levels; and vi) class VI mutants
(e.g., c.120del23 [9] or membrane-rescued F508del) impair
the plasma membrane stability of CFTR.
Conclusions
Several therapeutic strategies adopting this “mutation-spe-
cific” approach are currently under experimental testing or
clinical trial [3,6]. Based on the current “drug pipeline”,
these are expected to rise in numbers very soon.
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